Sign In
Buy NXGN
$23.94
+0 (+0%)
At Close: Feb 07, 2024
NextGen's (NXGN) Integrated Platform to Enhance Tribal Health
10:49am, Monday, 31'st Jan 2022
NextGen's (NXGN) integrated platform was adopted by a community health center in Northern California to meet the health requirements of American Indians/Alaska Natives.
Has Nextgen Healthcare (NXGN) Outpaced Other Medical Stocks This Year?
02:40pm, Friday, 28'th Jan 2022 Zacks Investment Research
Here is how Nextgen Healthcare (NXGN) and PureTech Health PLC Sponsored ADR (PRTC) have performed compared to their sector so far this year.
Has Nextgen Healthcare (NXGN) Outpaced Other Medical Stocks This Year?
10:46am, Friday, 28'th Jan 2022
Here is how Nextgen Healthcare (NXGN) and PureTech Health PLC Sponsored ADR (PRTC) have performed compared to their sector so far this year.
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
02:34pm, Thursday, 27'th Jan 2022 Zacks Investment Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
10:46am, Thursday, 27'th Jan 2022
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.
NextGen Healthcare Q3 Earnings Beat Consensus, Lifts FY22 Guidance
10:26am, Wednesday, 26'th Jan 2022 Benzinga
Provider of ambulatory-focused technology solutions, NextGen Healthcare Inc (NASDAQ: NXGN ) posted Q3 FY22 sales of $149.7 million , +6% Y/Y, beating the consensus of $146.32 million. Recurring revenue accounted for 90% of total revenue, or $134.5 million, growing 5% Y/Y. In Q3, subscription services revenue generated $41.2 million, up 8% Y/Y, driven by demand Full story available on Benzinga.com
NextGen Healthcare Q3 Earnings Beat Consensus, Lifts FY22 Guidance
05:26am, Wednesday, 26'th Jan 2022
Provider of ambulatory-focused technology solutions, NextGen Healthcare Inc (NASDAQ: NXGN) posted Q3 FY22 sales of $149.7 million, +6% Y/Y, beating the consensus of $146.32 million. Recurring reven
Nextgen Healthcare (NXGN) Q3 Earnings and Revenues Top Estimates
10:35pm, Tuesday, 25'th Jan 2022 Zacks Investment Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 14.29% and 2.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
NextGen Healthcare, Inc. (NXGN) CEO David Sides on Q3 2022 Results - Earnings Call Transcript
08:44pm, Tuesday, 25'th Jan 2022
NextGen Healthcare, Inc. (NXGN) CEO David Sides on Q3 2022 Results - Earnings Call Transcript
Nextgen Healthcare (NXGN) Q3 Earnings and Revenues Top Estimates
07:14pm, Tuesday, 25'th Jan 2022
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 14.29% and 2.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
NextGen Healthcare to Host Fiscal 2022 Third Quarter Results Conference Call on January 25
08:30am, Wednesday, 12'th Jan 2022
ATLANTA--(BUSINESS WIRE)--NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, today announced it will release its fiscal 2022 third quarter ended De
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
03:05pm, Monday, 03'rd Jan 2022 Zacks Investment Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
11:29am, Monday, 03'rd Jan 2022
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
Why Should You Hold Universal Health (UHS) in Your Portfolio?
07:56pm, Friday, 31'st Dec 2021 Zacks Investment Research
Riding high on strategic measures and a solid solvency level, Universal Health (UHS) holds prospects to reap benefits for investors.
Envista (NVST) Gets FDA 510 (k) Approval for N1 Implant System
04:27pm, Wednesday, 29'th Dec 2021 Zacks Investment Research
Envista (NVST) noted that the Nobel Biocare N1 system represents a significant step further in patient-centric dental implant solutions.
